Presentation Preview: Spotlighting the Translational Profile of KIVU-107 to Strive for Kinder & Gentler ADC Therapies with Enhanced Therapeutic Index
- Laying out rationale for pursuing less toxic ADC development to enable higher dosing and expand ADC therapeutic index
- Breaking down late-stage preclinical data of KIVU-107 in solid tumors to emphasize clinical opportunity and differentiation strategy
- Unveiling the emerging clinical profile of KIVU-107 to investigate how well preclinical data translates to patient responses and lay out ongoing clinical development strategy